Abstract. Glycosylation is known to play an important role in IgG antibody structure and function. Polymeric IgM, the largest known antibody in humans, displays five potential N-glycosylation sites on each heavy chain monomer. IgM can exist as a pentamer with a connecting singly N-glycosylated J-chain (with a total of 51 glycosylation sites) or as a hexamer (60 glycosylation sites). In this study, the N-glycosylation of recombinant pentameric and hexameric IgM produced by the same human cell type and culture conditions was site-specifically profiled by RP-LC-CID/ETD-MS/ MS using HILIC-enriched tryptic and GluC glycopeptides. The occupancy of all putative N-glycosylation sites on the pentameric and hexameric IgM were able to be determined. Distinct glycosylation differences were observed between each of the five N-linked sites on the IgM heavy chains. While Asn171, Asn332, and Asn395 all had predominantly complex type glycans, differences in glycan branching and sialylation were observed between the sites. Asn563, a high mannose-rich glycosylation site that locates in the center of the IgM polymer, was only approximately 60% occupied in both the pentameric and hexameric IgM forms, with a difference in relative abundance of the glycan structures between the pentamer and hexamer. This study highlights the information obtained by characterization of the site-heterogeneity of a highly glycosylated protein of high molecular mass with quaternary structure, revealing differences that would not be seen by global glycan or deglycosylated peptide profiling.
Introduction
I mmunoglobulin (Ig) M is the third most abundant antibody subclass in humans and plays an important role in the human immune system [1] [2] [3] . IgM is primarily involved in complement activation [4, 5] and immune surveillance by acting as a quality control mechanism in the body [2, 6, 7] . Recent discovery of a polymeric IgM specific receptor, FcμR, on B-and T-cells provided evidence of IgM playing a role in B-cell survival and immune system development [8] [9] [10] . In circulation, IgM is commonly present as a pentameric form, held together by a J-chain (Figure 1 ), which is required for translocation from the blood to the mucus layer on exposed epithelial surfaces [11] . Hexameric IgM is present naturally at a much lower concentration; in mouse, it was estimated to make up less than 5% of serum IgM [12] . However, serum from some patients with cold agglutinin disease was reported to have an increased amount of hexameric IgM present relative to healthy individuals. In addition, hexameric IgM was shown in vitro to be produced by the immune cells upon stimulation by bacterial lipopolysaccharide [13] . Functionally, hexameric IgM has been found to be better at activating the complement than pentameric IgM [12, 14, 15] , suggesting different functional roles for pentameric and hexameric IgM in the body. Structurally, each IgM monomer contains two heavy and two light chains, and has four domains in the constant region (Figure 1 ), similar to IgE [16, 17] . The monomers are polymerized into the pentameric or hexameric form via disulphide bridges in the endoplasmic reticulum [18] , and are transported into the Golgi apparatus for further processing as a polymerized protein [19] [20] [21] .
In humans, proteins can be modified by at least three main classes of N-glycans; high mannose, hybrid, and complex type N-glycans. The level of processing of the glycan has been shown to be, at least partly, determined by the accessibility of the glycosylation site to the immediate environment and glycosylation enzymes [22] . Glycosylation can affect the protein's overall structure, solubility, stability, and receptor binding affinity [23] . In IgG, single monosaccharide differences at the only N-glycosylation site on the heavy chain, Asn297, can drastically affect its function by altering the binding of IgG to the FcɣRIII [24] [25] [26] . Polymeric IgM is the largest and most glycosylated antibody in humans with five putative (NXT/S sequons) glycosylation sites on each IgM heavy chain (Asn171, Asn332, Asn395, Asn402, and Asn563), resulting in a total of 51 (with a single glycosylation site on the J-chain, Asn71) N-glycosylation sites on the pentameric IgM and 60 Nglycosylation sites on the hexameric IgM ( Figure 1 ). The distribution of classes of N-glycans across the five glycosylation sites is not uniform on human serum-derived IgM; glycopeptide analysis of the pentameric IgM found that Asn171, Asn332, and Asn395 had predominantly complex type N-glycans attached, whereas Asn402 and Asn563 had predominantly high mannose type N-glycans [27] [28] [29] . A recent publication has shown that sialylation differences on IgM can result in differential binding of IgM to T-cells, suggesting the importance of glycosylation in the IgM mediated immune response [30] .
Antibodies of the IgM isotype are gaining importance in the biological therapeutics industry, showing efficacy in autoimmune disease, inflammation, and cancer treatment [2, 7, [31] [32] [33] [34] [35] [36] [37] . Therapeutic IgMs are mostly produced recombinantly, with high product yield in cell systems, such as Chinese hamster ovary cells (CHO) and PER.C6® cells [38] , of which the glycosylation outcome is known to differ. The glycans at individual IgM glycosylation sites have been reported to be involved in various biological functions, including B-cell maturation (Asn171) [39] , complement activation (Asn402) [4, 40] , and J-chain incorporation (Asn563) [11, 41, 42] . Recently, in-depth characterization of the glycosylation of therapeutic proteins has become of interest to the pharmaceutical industry and the regulatory bodies because of the implications of glycosylation on host immune response and protein function [43] . In this study, a recombinant pentameric and hexameric human IgM, PAT-SM6 produced in the same human cell expression system as PER.C6® cells [44] under identical culture conditions, were used to investigate whether there are differences between the glycosylation of the two oligomeric variants of IgM. The original PAT-SM6 antibody was a natural pentameric IgM isolated from a patient with stomach cancer, and the recombinant form was previously under Phase I/II clinical trials for the treatment of multiple myeloma [37] . PER.C6® is a secretory human cell line derived from embryonic retina cells, and is reported to yield up to 500 mg/L of recombinant protein secreted into the culture supernatant [45, 46] . As the IgM antibody was produced by a human cell line, the resulting glycans are more likely to ensure compatibility as human biological therapeutics. In-depth characterization and comparison of the site-specific glycosylation between the pentameric and hexameric IgM provides a knowledge base for understanding how glycosylation affects the IgMmediated immune response and investigates whether polymeric protein N-glycosylation is affected by the level of polymerization.
Methods
Purified pentameric and hexameric PAT-SM6 human IgM were provided by Patrys Ltd. (Melbourne, Australia). Production including details of entire polypeptide sequences used, purification, quantitation, and oligomerization status characterization have previously been described [44] . Briefly, the pentameric (PAT-SM6 clone 123) and hexameric human IgM (PAT-SM6 clone 089) were expressed with identical genetic constructs, only differing by the absence of the J-chain gene sequence in the hexameric IgM expression vector, in the human cell line PER.C6®. The amino acid sequence of the IgM heavy chain Fc region is identical to the human IgM heavy chain in UniProt (P01871). Polymeric IgM was secreted into the culture supernatant and purified using a series of cation and anion exchange chromatography as described [47] .
Agarose Gel Electrophoresis of IgM Polymers
Pentameric (approximately 1 MDa) and hexameric IgM (approximately 1.2 MDa) produced by the PAT-SM6 clones 123 and 089 were purified as described [48] . Verification of the oligomerization state of the IgMs was performed by vertical agarose gel electrophoresis. The agarose gel was prepared by melting agarose powder (Amresco, Sydney, Australia) (1.7%) (w/v) in Tris acetate ethylene-diamine-tetra-acetic acid (TAE), pH 8.6, with a microwave on high power until agarose powder was completely dissolved. Molten agarose was then poured into a prewarmed (50°C) 1.5 mm Novex gel cassette (Life Technologies, Melbourne, Australia) for polymerization at room temperature. NuPAGE LDS loading buffer (1×) (Life Technologies) was added to~5 μg of pentameric or hexameric IgM and left at room temperature for 30 min before loading on the agarose gel. A DNA ladder (Genscript Ready-to-load 100 bp ladder) was used as a molecular mass marker. Electrophoresis was carried out at 35 V for about 2.5 h using TAE as the running buffer with 0.01% (w/v) sodium dodecyl sulphate (SDS) in the cathode reservoir. After the electrophoresis, the gel was removed from the cassette and stained with GelRed (Biotium, Sydney, Australia) as per manufacturer's instructions for 10 min. The gel was then imaged under UV (Gel Doc EZ; Biorad) to visualize the DNA bands. A subsequent staining step using Coomassie Brilliant blue (Sigma, Sydney, Australia) was performed to visualize the protein bands. The agarose gel was destained with a solution consisting of 40% ethanol and 10% acetic acid (v/v), microwaved for 10 s, and left on a shaker for 10 min. The destaining procedure was repeated until the background was low and protein bands visible. The gel was then imaged under UV again.
Multiple Reaction Monitoring (MRM) of J-Chain Containing IgM
To verify the presence/absence of the J-chain in the IgM, MRM was performed, adapted from a previous report [49] , on an in-solution tryptic digest of the pentameric and hexameric IgM. Briefly, equal amounts of IgM (10 μg) were reduced with 10 mM dithiothreitol (Sigma) at 80°C for 30 min and subsequently alkylated with 50 mM iodoacetamide (Sigma) at room temperature, in the dark, for 1 h. Cold acetone was then added (9 volume equivalent) to precipitate the IgM at -20°C for 2 h, and the protein pellet collected by centrifugation at maximum speed with a benchtop centrifuge for 20 min. The protein pellet was resuspended in 30 μL of 100 mM ammonium bicarbonate, pH 8, for tryptic digest (3% (w/w) porcine trypsin (Promega, Sydney, Australia)) at 37°C overnight. The peptides were then desalted using a C18 tip (Millipore, Melbourne, Australia) before injection onto a nanoLC-MS/MS using a QExactive mass spectrometer (Thermo) for routine protein identification analysis using data-dependent acquisition as previously described [50] . The result was used to generate the list of observed peptides and the top 25 peptides (Supplementary Table T1 , 20 from IgM heavy chain, 5 from J-chain) were selected for MRM analysis. One μg of peptides from pentameric and hexametric IgM were analyzed on the Q-Exactive platform using targeted MS2 mode at a resolution of 17,500 at m/z 400. Data analysis and quantitation of the MRM data was performed using Skyline [51] .
Preparation of Glycopeptides from Reduced IgM
Pentameric and hexameric IgM (20 μg) were reduced in SDS-PAGE loading buffer (Life Technologies) supplemented with 10 mM dithiothreitol at 70°C for 30 min and subsequently alkylated with 50 mM iodoacetamide at room temperature, in the dark, for 1 h prior to loading into a 4%-12% (w/v) Bis-Tris gradient gel (Life Technologies). The subunits were then resolved by gel electrophoresis at 150 V for 1.5 h and stained with Coomassie Brilliant Blue (Sigma). The band corresponding to the IgM heavy chain (approximately 70 kDa) and J-chain of the pentamer (approximately 20 kDa) was excised, destained, and washed in 100 mM ammonium bicarbonate buffer, pH 8, prior to protease digestion using either 3% ( w / w ) p o r c i n e t r y p s i n ( P r o m e g a ) o r 3 % ( w / w ) Staphylococcus aureus V8 GluC (Roche, Sydney, Australia) separately. Approximately 30% of the extracted peptides were used to monitor the ratio of glycosylated to non-glycosylated peptides (i.e., site occupancy). This fraction was desalted using a C18 tip (Millipore) before injection onto a capillary LC-MS/ MS (see below). The remainder of the peptide digests were dried and enriched for N-glycopeptides using zwitterionic hydrophilic interaction liquid chromatography (ZIC-HILIC) in a solid phase extraction (SPE) format.
ZIC-HILIC SPE Enrichment of Glycopeptides
ZIC-HILIC SPE enrichment of glycosylated peptides was performed as previously described with minor modifications [52, 53] . Briefly, ZIC-HILIC resin (10 μm particle size, 200 Å pore size, kind gift from Sequant, Merck, Sweden) were packed on top of a C18 tip (Millipore) to an approximate column height of 5 mm using a table top centrifuge. The column was first washed with 1% (v/v) trifluoroacetic acid (TFA) then equilibrated with 1% (v/v) TFA in 80% (v/v) acetonitrile (ACN). The dried peptide mixtures were reconstituted in 20 μL 1% (v/v) TFA in 80% (v/v) ACN. After loading sample onto the column, the flowthrough fraction was reloaded back onto the same column twice to optimize the hydrophilic glycopeptide binding. The column was then washed twice with 50 μL 1% (v/v) TFA in 80% (v/v) ACN, before the bound glycopeptides were eluted twice with 20 μL 1% (v/v) TFA. A subsequent elution with 20 μL 1% (v/v) TFA in 80% (v/v) ACN was performed to elute any glycopeptides that might be bound to the C18 base of the tip during the elution. The enriched glycopeptides were dried before reconstitution in 15 μL deionized water for capillary LC-MS/MS (see below) in high recovery glass vials (Agilent, Sydney, Australia).
Site Occupancy Analysis Before and After Deglycosylation
As non-glycosylated IgM heavy chain peptides were seen in the unenriched IgM heavy chain peptide mixtures, each glycosylation site occupation was estimated by comparing the deglycosylated (Asn to Asp; Δm = +1 Da) and non-glycosylated forms of the same peptides after N-glycosidase F digestion of the heavy chains. This approach has the advantage of limiting potential ionization differences between glycosylated and nonglycosylated peptides and simplifies the site occupancy analysis by comparing the relative ion intensity of the de-and nonglycosylated peptides [54] . The gel bands (n = 3 for both pentameric and hexameric IgM) corresponding to glycosylated IgM heavy chain (~70-75 kDa) were excised, destained, and washed with 100 mM ammonium bicarbonate pH 8 (Sigma) prior to deglycosylation by 3 U peptide N-glycosidase F (Roche) overnight (approximately 16 h) at 37°C in the same buffer. Released glycans were extracted twice in 50% (v/v) ACN, and the deglycosylated protein was digested with trypsin (Promega) as described above. The resulting peptides were then extracted and desalted as described above for LC-MS/MS analysis.
Capillary RP-LC-MS/MS CID/ETD of IgM Glycopeptides
Extracted trypsin and GluC digested IgM peptides were analyzed separately using on-line capillary reversed phase (RP) (ProteCol C18, 300 μm i.d., 10 cm, 5 μm particle size, 300 Å pore size; SGE Analytical Science, Melbourne, Australia) liquid chromatography (LC) (Ultimate 3000 LC; Dionex, Thermo Fisher Scientific, Sunnyvale, CA, USA) mass spectrometry (MS) (HCT 3D ion trap; Bruker, Preston, Victoria, Australia) in positive polarity mode with either resonance activationcollision induced dissociation (CID) or electron transfer dissociation (ETD) fragmentation mode. The column was equilibrated in 100% solvent A [0.1% (v/v) formic acid (Sigma)] and the peptides separated by a two-step gradient of 0%-30% (0.5%/min slope) solvent B (0.1% (v/v) formic acid in ACN), followed by 30%-60% solvent B (4.2%/min slope) before washing the column in 80% B for 10 min and re-equilibration for 10 min in starting solvent conditions. A constant flow-rate of 5 μL/min was used with the column heated to 50°C. The peptide mixtures were reconstituted in 15 μL of deionized water and 5 μL was injected onto the column. For CID fragmentation mode, MS full scans (m/z 300-2200) acquired with a scan speed 8100 m/z/s, a rolling average of 2, an ion count control target of 200,000, a precursor isolation width of 4 Th, and a maximum accumulation time of 200 ms) was followed by MS/MS acquisition of the four most abundant precursor signals in each full scan, using ultrahigh purity helium (99.999% purity; BOC, Sydney, Australia) at 85-90 psi as a collision gas. For ETD fragmentation mode, the two most abundant precursor signals in each full scan were selected for fragmentation (m/z 300-2200, acquired with a scan speed 8100 m/z/s, a rolling average of 2, an ion count control target of 200,000, maximum accumulation time 200 ms, a precursor isolation width 4 Th, ion count control reactant target ETD 600,000, average reactant accumulation time 7-20 ms (maximum accumulation time 200 ms), reaction time 150 ms). ETD fragmentation was carried out using fluoranthene with ultra-high purity methane gas (99.999% purity, BOC) at 35-37 psi as a carrier gas).
Data Analysis of Glycopeptides
A theoretical list of the possible N-glycosylation site containing peptides and their precursor masses was generated using GPMAW (Lighthouse, Odense, Denmark), based on the canonical human IgM sequence in UniProt (P01871). This software was also used to generate the theoretical b/y-, c/z-, and the Y1-(peptide + GlcNAc) fragment ions of the putatively Nglycosylated peptides, based on theoretical trypsin or GluC cleavage sites. Glycopeptide clusters in the LC-gradient were identified using MS/MS extracted ion chromatograms (EICs) to search for clusters of glycopeptide precursors giving rise to diagnostic oxonium ions upon CID fragmentation; m/z 292 (NeuAc), m/z 366 (Hex-HexNAc), m/z 657 (NeuAc-HexHexNAc-), and/or m/z 690 (Hex 3 -HexNAc). The identities of the glycopeptide clusters were verified using the list of theoretical glycopeptides and their fragment ions. The acceptable mass difference between theoretical and calculated mass is set at charge * 0.4 Da (mass accuracy of ion trap). Only precursor ions that corresponded to potential glycopeptides and having associated interpretable MS/MS fragment spectra were included in the analysis. Such identified glycopeptides were quantified by area-under-curve (AUC) of all of their respective EICs derived from all of their observed charge states. The percentage relative abundance of each glycopeptide form with a glycosylation site was calculated against the summed AUC of all identified glycopeptides with that particular site. Glycan structural approximation was based on the identified monosaccharide composition and previously reported glycan structural features of PER.C6® proteins [45] . Based on current knowledge of mammalian N-glycosylation, the monosaccharide mass of 146.1 Da (deoxyhexose) will be considered as fucose (Fuc). Any potential differences between the pentameric and hexameric IgM site-specific glycosylation was statistically assessed for the individual glycan types (high mannose, hybrid, and complex subtypes) at the individual sites by using a twotail Student's t-test with a 95% confidence threshold. All sitespecific glycoprofiles of pentameric and hexameric IgM and site occupancy assessments were performed in technical duplicates (individual gel bands) for both trypsin and GluC proteolytic digests (n = 2).
Results and Discussion

Agarose Gel Electrophoresis of Intact IgM Polymers
To verify the oligomerization differences between PAT-SM6 clone 089 IgM and PAT-SM6 clone 123 IgM used in this study, the intact IgM molecules were resolved using vertical agarose gel electrophoresis (Figure 2 ). The addition of SDS to the cathode buffer was required to maintain IgM in solution and aid in the negative charge distribution for the migration of the protein. The proposed pentameric PAT-SM6 clone 123 IgM migrated faster than the hexameric PAT-SM6 clone 089 IgM [44] , confirming a lower polymeric state. As there is a lack of Figure 2 . Agarose gel (1.7%) (w/v) imaged under UV exposure after staining with Coomassie blue. Coomassie blue-stained proteins were UV absorbing, and appeared as a shadow under UV excitation. PAT-SM6 clone 089 IgM, which was previously shown to be a hexamer [43] , had a slower migration rate than PAT-SM6 clone 123 IgM, indicating that PAT-SM6 clone 123 was of a lower MW. The migration of the DNA ladder is used to show that the protein bands are of high molecular weight (2000 bp is approximately 1.3 MDa).
very high molecular mass protein markers covering this mass range (>800 kDa), a DNA ladder was used, as the commercial NativePAGE protein marker (Life Technologies) is not compatible with this agarose gel system. As DNA is highly negative charged, the addition of SDS in the cathode buffer might alter its migration; hence, the molecular mass (by base pairs calculation) only served as a crude estimate of molecular mass. The human IgMs resolved as smears, which was attributed to the micro-and macro-heterogeneity of the IgM N-glycosylation and is similar to the diffuse bands seen in the heavily glycosylated high molecular mass mucin gel separations [55] . This was substantiated by an MRM experiment where the Jchain peptides were only detected in the IgM polymer from clone 123, and absent in the IgM polymer from clone 089 (Supplementary S1a). To further check the purity of the IgM preparations, the ratio of IgM heavy chain:J-chain of the IgM polymer from clone 123 was estimated to be approximately 12:1 instead of the theoretical 10:1, suggesting that PAT-SM6 clone 123 produces at least 85% pentameric IgM (Supplementary S1b). From here on, PAT-SM6 clone 123 IgM will be referred to as the pentameric form, and PAT-SM6 clone 089 IgM as the hexameric form.
Reversed Phase LC-MS/MS Separation of ZIC-HILIC Enriched IgM Glycopeptides
When present in a complex peptide mixture, non-glycosylated peptides ionize more efficiently [54] , resulting in an underrepresentation of glycosylated peptide abundance and lack of MS/MS acquisition for further identification. Enrichment of glycosylated peptides decreases the competition of ions and enhances the detection of the glycopeptides. ZIC-HILIC enrichment of IgM peptides efficiently partitioned glycosylated peptides from non-glycosylated peptides; after enrichment, the majority of the observed MS signals were identified as being glycopeptides ( Figure 3 , (aiii, aiv) and (biii, biv)). We have previously shown that ZIC-HILIC enriches N-glycopeptides in an unbiased fashion when the experimental settings such as column capacity and the mobile and stationary phases are considered [52] . Presence of sialic acid residues on the enriched glycopeptides can result in a slightly delayed retention on the subsequent reversed phase chromatographic separation [56] . In support of this, shoulder peaks were observed with the GluC Asn395-glycopeptide [AVKTHTNISE, Figure 3b (iv), 19-21 min, 21-22 min] , where the population of the sialylated glycoforms were identified to be in the later eluting peak. All five glycosites were identified from the trypsin (Asn171, Asn332, and Asn563) and GluC (Asn395, Asn402, and Asn563) digests.
Identification of Glycopeptides Using CID Fragmentation
Use of tandem MS fragment ions for peptide sequence identification has become a requirement for any peptide-oriented experiment since a single mass, even when measured at high mass accuracy, can correspond to multiple different peptides. For glycopeptides, this becomes even more important as most glycosylated peptides have a number of different glycan compositions and structures attached. Although in-depth glycan structural features such as sialic acid linkages, antennary GlcNAc branching, and outer arm Fuc linkages could not be solved using intact glycopeptide approaches, the presence of some structural features can be deduced from the glycopeptide tandem MS fragment ions, monosaccharide composition, and pre-existing N-glycosylation biosynthetic pathways. Confident identification by using CID fragmentation of glycopeptides derived from peptide mixtures of low complexity has been previously described [56, 57] ) that contain other spontaneous chemical modifications where the exact amino acid modified could not be identified ion series that still contain the mass of the intact peptide backbone, with the Y1-ion corresponding to the peptide still conjugated with a GlcNAc ± Fuc. Identifying the Y-ion series of a N-glycosylated peptide is relatively straightforward; all the N-glycopeptides from about the same elution time would have a similar subset of fragment ions that corresponds to the intact peptide with decreasing masses of the attached N-glycan core structures (from core Man 3 GlcNAc 2 ± Fuc down to GlcNAc ± Fuc) (Figure 4 ). These fragment ions were matched against the theoretical Y-ion series of the predicted glycopeptides (containing the NXT/S sequon) to determine the peptide identity. For instance, based on the theoretical mass, the tryptic Asn171-glycopeptide with a single missed cleavage, YKNNSDISSTR, will appear at m/z 1284.6
1+
. The theoretical glycopeptide mass with the monosaccharides forming the N-glycan core structure can be generated in silico, and accounted for as doubly and triply charged m/z values; for this example, the doubly charged To be noted in the interpretation of CID spectra are chemical modifications of the peptide backbone that result in presence of additional glycopeptides clusters (Figure 3 ). These modifications can be experimental artefacts and can lead to the incorrect assignment of the glycan composition on the peptide. For example, alkylation by iodoacetamide (Δm = +57 Da) and oxidation (Δm = +16 Da) of the methionine are possible peptide modifications observed in peptide-based mass spectrometry [58] . However, some of these modifications (alone or in aggregate) have the same mass as the monosaccharide mass differences between a hexose (glucose, galactose, mannose, 162 Da) and a fucose (146 Da) equating to Δm = 16 Da, and the mass difference between a HexNAc (GlcNAc, GalNAc, 203 Da) and a fucose equal to Δm = 57 Da. Apart from alkylation of the methionine (+57 Da) (Supplementary S3) we also observed peptide N-terminal Schiff base formation (Δm = +26 Da) [59] (Supplementary S2), which were accompanied with a deviation in reversed phase retention time and a unique series of Y-ions. In our experience, while these uncommon modifications are not high in abundance (<10%) and cause little bias in the subsequent relative quantitation of the glycopeptides, it should be taken into account if the exact molar distributions of glycoforms at each site were desired.
Site Occupancy Analysis of Asn563-Glycosylation
The occupancy of each glycosylation site was first checked by the presence of non-occupied glycopeptides using a standard MASCOT search of the unenriched gel extracted peptide samples. No masses corresponding to the theoretical non-glycosylated tryptic or GluC peptides were seen when assessing four of the potential sites (i.e., Asn171, Asn332, Asn395, and Asn402), suggesting that these were fully occupied. This is consistent with previous reports based on analysis of human serum IgM [27] [28] [29] . In contrast, non-glycosylated Asn563 peptides were detected. Occupancy of this site was then estimated by comparing peptide N-glycosidase F deglycosylated (observed experimentally as a deamidated (Δm = +1 Da) peptide) and nonglycosylated peptides of Asn563 (Supplementary S4a) in a separate experiment. Importantly, spontaneous deamidation of the Asn to Asp was assessed and found not to be present, (Supplementary S4b). The Asn563 occupancy was estimated to be approximately 60% for both the pentameric and hexameric IgM, which translates to an average of about six out of 10 possible Asn563 sites being occupied in any given molecule of the pentameric IgM and seven out of 12 possible Asn563 sites being occupied in hexameric IgM molecules. This differs from recent reports of the glycosylation of human serum IgM that found Asn563 to be fully occupied with N-glycans [27, 28] . Another recent report on human serum IgM reported under-occupied Asn563 using MRM but reported an Bunoccupancy^of only 0.1% of human serum IgM Asn563 [29] . These reports suggest the relative abundance of nonglycosylated Asn563 is very low. An earlier report, however, reported incomplete occupancy of Asn563 on human serum IgM [60] , as estimated by the relative abundance of released and labelled N-glycans. The authors calculated that there should be a relative abundance of released high mannose type N-glycans of approximately 40% if Asn402 and Asn563 were fully occupied. A total abundance of only 23.4% high mannose structures was observed, indicating approximately 17% glycosylation of Asn563, based on a fully occupied Asn402. Compared with the intact glycopeptide/peptide analysis presented here, the study employed an indirect approach of analysis of IgM released glycans, and experimental issues such as protein purity, incomplete deglycosylation, unequal labelling efficiencies, individual biological variation, and sample losses from additional clean-up procedures might result in bias [61] .
For this work, the difference in Asn563 occupancy from human serum IgM might be due to the difference in sample origin; human serum IgM is predominantly secreted from the whole B-cell population in the pentameric form, whereas PAT-SM6 is a recombinant human IgM produced from human cell culture. Two prior reports on incomplete occupation, estimated by amino acid to carbohydrate content of Asn563-glycopeptides of mouse IgM (44% occupancy, MOPC 104E cells) [62] , and human IgM (40%-50% occupancy, human-human-mouse hybridoma) [63] were both from cultured cells. Recombinant production of IgM, as analyzed in this study, is performed using an inducible promoter, under conditions where protein overexpression occurs. Insufficient glycan precursor and/or nucleotide sugar substrates during protein overexpression has been shown to change the glycosylation site occupancy as did cell culture conditions such as temperature and presence of metal ions [64] . Taken together, glycoanalysis methods and expression conditions may account for these variable reports on different site glycosylation differences in IgM. Alternatively, the variable site occupancy could also result from differences in protein folding rates, transfer of glycan precursor, J-chain incorporation, and IgM polymerization. In addition, we would like to point out that as IgM is a polymeric protein, estimation of site occupancy at the peptide level might not truly reflect the occupation of the intact protein. For example, a site occupation of 60% can be interpreted as 60% of the heavy chains in each IgM polymer being occupied at that site, or as 60% of the IgM polymers having fully occupied Asn563 while the remaining 40% polymers are completely unoccupied at the Asn563 site. This possibility can only be determined in the future by top down intact protein mass analysis.
Comparison of Site-Specific Glycosylation of Pentameric and Hexameric IgM
Pentameric and hexameric IgM used in this study were produced recombinantly in culture from the same cell type, PER.C6® [44] under identical conditions, and should thus, in principle, be processed by a similar set of glycosylation machineries. The relative abundance of glycans on the entire IgM heavy chain, normalized by site occupancy of the pentameric and hexameric IgM, is shown ( Figure 5) . Overall, the Asn171, Asn332, and Asn395-glycosylation displayed predominantly complex type N-glycans, whereas Asn402 and Asn563 displayed predominantly high mannose type N-glycans on both IgM forms. This is consistent with previous glycopeptide studies on the pentameric form [27] [28] [29] 60] or on mixtures of pentameric and hexameric human IgM [63, 65] . The wellstudied biosynthesis of N-glycans progresses from high mannose to hybrid to complex type, indicating that the glycans on Asn402 and Asn563 were less processed than the three more N-terminal sites.
Difference in glycosylation of monomeric and pentameric IgM was previously observed by differential electrophoretic mobility of the IgM heavy chain [66] . Glycans on the monomeric IgM were more processed than pentameric IgM; monomeric IgM mu heavy chain had increased galactosylation and slower electrophoretic mobility of the heavy chain than the mu heavy chain of pentameric IgM [21] . This indicates that apart from glycosylation site accessibility [22] , polymerization of oligomeric proteins can cause glycosylation sites to become less accessible. Hence, any differences observed in the glycosylation of the pentameric and hexameric IgM may be related to the oligomerization status; the sixth component of pentameric IgM is the J-chain, while the sixth component of hexameric IgM is a sixth identical monomer (Figure 1 ). Molecular modeling of pentameric IgM suggests differential accessibilities of the five glycosylation sites; the exterior glycosylation sites (i.e., Asn171, Asn332, and Asn395) are more solvent exposed and thus accessible to enzymes for processing, whereas the interior glycosylation sites Asn402 and Asn563 are relatively hidden and inaccessible to the glycosylation processing enzymes [21, 27, 60] . This highlights the importance of performing site-specific characterization of polymeric glycoproteins with multiple N-glycosylation sites as total glycosylation characterization of the whole protein will not reveal the differences in the individual site-specific glycosylation distribution.
Complex N-Glycosylation at Asn171, Asn332, and Asn395
On the whole, when the glycopeptides were site-specifically grouped into glycan types of high mannose, hybrid, complextype (subdivided into mono-antennae, bi-antennary, tri- Figure 5 . Overview of the relative abundance of glycan types (occupancy normalized) across each of the five N-glycosylation sites on the mu heavy chain of the pentameric and hexameric IgM, clustered into glycan types (high mannose, hybrid, mono-antenna, biantennary, and tri-antennary -with and without sialylation [neutral] ). Relative quantitation is based on area under curve of the respective extracted ion chromatogram. Asn171 and Asn332 were characterized using the tryptic digest (n = 2), and Asn 395 and Asn402 were characterized using the GluC digest (n = 2). For Asn563, which was identified from both the trypsin and GluC digests, the combined data is shown (n = 4). Specific glycan compositional abundance can be found in Figure S3 . ** P < 0.001, *** P < 0.0001 antennary) with (anionic) and without (neutral) sialylation, the glycosylation types were found to be similar for the individual sites of pentameric and hexameric IgM ( Figure 5 ). However, the radial sites (i.e., Asn171, Asn332, and Asn395) displayed different glycan type profiles, even though they all contained predominantly complex-type glycans. Hybrid-type N-glycans were exclusively identified on the Asn171 and made up approximately 40% of the glycans at this site, consistent with a previous study [65] . Cleavage of the terminal mannose residues from the intermediate hybrid structure precursors is a necessary step to form the complex glycans, and this may be obstructed at Asn171. Both Asn332 and Asn395 have their N-glycans further processed than Asn171, as evidenced by the attached biand tri-antennary glycans. The degree of sialylation was different at these two sites, with a higher degree of sialylation found at Asn332 (approximately 65%) than on Asn395 (approximately 40%). It is important to note that our glycan type assignment was based on glycopeptide data relying on monosaccharide compositions, prior knowledge and certain glycan feature diagnostic masses rather than glycan structures; thus, glycans classified as being Btri-antennary^may also include biantennary structures, which additionally displayed bisecting GlcNAcs, lactosamine repeats or LacdiNAc epitopes. Although some of these glycans could be classified as being part of the bi-antennary type, bisecting lactosamine and LacdiNAc epitopes are all unique structural features that differ from the regular bi-antennary glycans. While diagnostic tandem MS fragment ions might be able to distinguish the presence of some of these structures (e.g., m/z 407 1+ , HexNAc 2 ; m/z 698 1+ , NeuAcHexNAc 2 from LacdiNAc containing glycans; Y-ion specific for HexNAc 2 Hex 1 HexNAc 1 of bisecting glycans [67] ), isobaric glycopeptides with the same composition but different structures are not resolved well enough by the capillary C18 column to distinguish them.
The three N-terminally located glycosylation sites reside on separate domains of the Ig mu heavy chain; Asn171 in C H 1, Asn332 in C H 2, and Asn395 in C H 3. Although it is not known how each of these sites affects the polymeric IgM biological function, it has been reported that Asn171-glycosylation of cell surface monomeric IgM is required for B-cell development [39] . The binding site of complement component C1q to IgM is located at the C H 3 domain [68] , and binding has been identified to be based on electrostatic interactions [69] , suggesting that the sialylation, which imparts a negative charge on the Asn395 glycans in the C H 3 domain, could affect complement binding. Sialylation has been previously reported to affect complement binding; desialylated murine IgM was shown to activate complement more efficiently than the untreated counterpart [70] . Sialylation was also recently found to affect human IgM binding to T-cells where sialylated IgM was internalized, whereas desialylated IgM remained bound to the T-cell surface [30] . As the majority of the sialylated glycans on IgM were located on Asn171, Asn332, and Asn395, it suggests that these three sites may play a role in IgM binding to the receptor on the T-cell surface. No significant glycan type differences were observed between these sites on pentameric and hexameric IgM.
High Mannose Containing Asn402
Asn402 is located on the C H 3 domain of the Ig mu heavy chain, and is described to be homologous to the single IgG N-glycosylation site (Asn297) [40, 71] , and to the single high mannose site amongst the seven N-glycosylation sites of human IgE (Asn394) [67] . These three sites have all been demonstrated to be important for antibody-receptor binding; IgG to FcɣRIII [24] , IgM to complement [40] , and IgE to FcɛRI [67] . For mouse IgM, it was also found that upon mutagenesis of the nearby amino acid Ser406Asn resulted in abnormal Asn402 glycosylation as determined by electrophoretic migration, and resulted in a decrease in the ability of IgM to activate complement [4] . In the same model, when IgM was synthesized in the presence of 1-deoxymannojirimycin, which inhibits the processing of N-glycans and results in predominantly immature Man9 glycans, the activation of complement by the Ser406Asn mutant IgM was slightly restored. This suggests that the glycosylation at Asn402 is important, and that high mannose-type glycans at this site may play a role in complement activation. This was also observed in human IgE, where the single high mannose containing Asn394 was required for IgE binding to FcɛR [67] . The Asn402 glycosylation of pentameric and hexameric IgM appears highly conserved, even at the individual glycan compositional level (R 2 = 0.9953, Supplementary S5). The Man5 glycan was also observed predominantly on human serum IgM at this site [27] , indicating that both pentameric and hexameric forms of PAT-SM6 IgM are glycosylated in a similar manner to human serum IgM at Asn402.
Tail Piece Glycan Asn563
The innermost Asn563 glycosylation site of polymeric IgM situated at the C-terminus region of the IgM mu heavy chain is termed the tail piece since it is located in the last 20 amino acids of the C-terminus. This is the region to which the J-chain is bound to the pentameric IgM [42] . The amino acid sequence of the Asn563 site is highly conserved between a wide range of animals, including human, mouse, chicken, frog, and fish. Absence of glycans at Asn563 has also been shown to cause increased IgM avidity towards its antigen [72] . Furthermore, glycans at Asn563 were reported to play a role in J-chain incorporation into the pentameric IgM [11, 41, 42] , and the presence of the J-chain decreases complement activation; J-chain deficient pentameric IgM activates complement twice as well as J-chain incorporated pentameric IgM [11] . Together, this makes the glycosylation of Asn563 an interesting point of study. The occupancy of Asn563 in this study was observed to be approximately 60% for both the recombinant pentameric and hexameric IgM (Supplementary S4a). This is not in agreement with previous reports on human serum IgM reporting full Asn563 occupancy [27, 28] . Also differing from previous characterization studies of pentameric IgM [28, 29, 60] or of mixtures of pentameric and hexameric IgM [63, 65] that reported exclusively high mannose type N-glycans at Asn563, this study also identified hybrid, complex, and sialylated Asn563-glycans at low abundance (approximately 5% and 15% on pentameric and hexameric IgM, respectively, Supplementary S6). This was confirmed by analysis of both tryptic and GluC glycopeptides (Supplementary S5); the GluC Asn563 glycopeptides were more readily identified rather than the tryptic variants, substantiating recent publications arguing that single protease proteomics-based experiments might result in bias or lack of data completeness [73] [74] [75] . Furthermore, the relative abundance of the bi-antennary complex glycans characterized on this innermost Asn563 was significantly higher in hexameric (7.9%) than pentameric (2.6%) IgM (p < 0.0001) with a concomitantly lower high mannosylation of the hexameric (44.6%) relative to the pentameric (55.3%) IgM (p < 0.001) at this site ( Figure 5 ). This difference may be correlated to the absence of the Jchain in the hexameric form. The J-chain glycopeptide of pentameric IgM was also analyzed (Supplementary  Table T2 ). Our data agrees with other studies reporting full occupancy of the J chain exclusively by complextype N-glycans at the single Asn71-glycosylation site [28, 60] . The complete processing of the J-chain glycans to complex type N-glycans suggests that the Asn71 of the Jchain is highly accessible [22, 60] compared with the proximal Asn563 on the pentameric IgM heavy chain and might also obstruct the processing of Asn563 glycans. For the hexamer, absence of the J-chain could allow increased access to the mannosidase to process the glycans down to the Man5 producing the subsequent complex and sialylated structures (i.e., higher Man5 and hybrid/complex type glycans seen on the hexamer, Supplementary S5). However, the accessibility to the hexameric IgM interior is still low, as the hybrid/complex type glycans only account for approximately 15% of the Asn563 glycans. Although it does not fully answer any questions pertaining to the biological relevance of the processed glycans at Asn563, it remains as evidence of protein complex formation/polymerization affecting the glycosylation process.
Considering that a glycosylated Asn563 is required for J-chain incorporation [11, 41, 42] , it is, however, not known how many occupied Asn563 sites are required for J-chain incorporation per polymerized IgM, or if the processing of Asn563 to complex type glycans hinders J-chain incorporation. The latter is unlikely, as polymerization was reported to be completed in the endoplasmic reticulum [19, 21] whereas the processing of glycans occurs in the Golgi apparatus. It was also hypothesized that J-chain expression could be a mechanism for B-cells to regulate the amount of circulating hexamers [11] as a mode for combating more serious infections [76] . For this study, the hexamer was recombinantly produced in the absence of the J-chain sequence, so information on glycan-mediated assembly of the IgMs by the presence of this chain could not be obtained.
Conclusion
Currently, the emergence of the glyco-engineered IgG antibodies (e.g., obinutuzumab, Genentech), where the glycans on the Fc region are engineered to contain a single specific glycan structure, has received remarkable attention due to the increased biological activity [77] . As more glyco-engineered therapeutic proteins enter the market, in-depth glycan characterization becomes very important, especially in cases where there are multiple glycosylation sites such as on IgM. However, it is still technologically challenging to perform site-specific glyco-engineering for such glycoproteins since we do not fully understand how glycosylation is regulated at the site-specific level on these very large polymeric molecules.
